Medtronic (NYSE: MDT) is a good buy in late 2026 because stars such as value, growth, guidance, partnerships, and dividends are aligning. They point to sustained outperformance and potential acceleration but, more importantly, to robust capital returns.
While share buybacks are at token levels, barely enough to offset dilutive forces and reduce the share count, dividends are more substantial. The dividend is among the top reasons to buy this stock, yielding over 3% with shares near long-term lows. Additionally, MDT is just one increase away from being crowned Dividend King.
